Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 838 - 846 |
| Number of pages | 9 |
| Journal | Clinical Endocrinology |
| Volume | 70 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2009 |
Cite this
}
Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). / Chapman, Ian; Greville, Hugh; Ebeling, Peter Robert; King, Susannah Jane; Kotsimbos, Tom C; Nugent, Patricia; Player, Rosie; Topliss, Duncan J; Warner, Janet; Wilson, John W.
In: Clinical Endocrinology, Vol. 70, No. 6, 2009, p. 838 - 846.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF)
AU - Chapman, Ian
AU - Greville, Hugh
AU - Ebeling, Peter Robert
AU - King, Susannah Jane
AU - Kotsimbos, Tom C
AU - Nugent, Patricia
AU - Player, Rosie
AU - Topliss, Duncan J
AU - Warner, Janet
AU - Wilson, John W
PY - 2009
Y1 - 2009
N2 - Reduced bone mineral density (BMD) and increased rates of atraumatic fracture are observed in cystic fibrosis (CF) patients, causing increasing morbidity as this population ages. The study aimed to assess the safety, tolerability and effect on BMD of intravenous zoledronate in adults with CF and osteopenia.
AB - Reduced bone mineral density (BMD) and increased rates of atraumatic fracture are observed in cystic fibrosis (CF) patients, causing increasing morbidity as this population ages. The study aimed to assess the safety, tolerability and effect on BMD of intravenous zoledronate in adults with CF and osteopenia.
UR - http://www3.interscience.wiley.com/cgi-bin/fulltext/121421127/PDFSTART
U2 - 10.1111/j.1365-2265.2008.03434.x
DO - 10.1111/j.1365-2265.2008.03434.x
M3 - Article
VL - 70
SP - 838
EP - 846
JO - Clinical Endocrinology
JF - Clinical Endocrinology
SN - 0300-0664
IS - 6
ER -